325
Views
6
CrossRef citations to date
0
Altmetric
Brief Report

Inhibition of brain retinoic acid catabolism: a mechanism for minocycline's pleiotropic actions?

, , , , &
Pages 634-640 | Received 19 Dec 2014, Accepted 23 Mar 2015, Published online: 05 Jun 2015

References

  • Abu-Abed S, Dolle P, Metzger D, Beckett B, Chambon P, Petkovich M. 2001. The retinoic acid-metabolizing enzyme, CYP26A1, is essential for normal hindbrain patterning, vertebral identity, and development of posterior structures. Genes Dev 15:226–240.
  • Aoto J, Nam CI, Poon MM, Ting P, Chen L. 2008. Synaptic signaling by all-trans retinoic acid in homeostatic synaptic plasticity. Neuron 60:308–320.
  • Bremner JD, Shearer KD, McCaffery PJ. 2012. Retinoic acid and affective disorders: the evidence for an association. J Clin Psychiatry 73:37–50.
  • Casha S, Zygun D, McGowan MD, Bains I, Yong VW, Hurlbert RJ. 2012. Results of a phase II placebo-controlled randomized trial of minocycline in acute spinal cord injury. Brain 135:1224–1236.
  • Chiu AM, Chuenkongkaew WL, Cornblath WT, Trobe JD, Digre KB, Dotan SA, et al. 1998. Minocycline treatment and pseudotumor cerebri syndrome. Am J Ophthalmol 126:116–121.
  • Corcoran JP, So PL, Maden M. 2004. Disruption of the retinoid signalling pathway causes a deposition of amyloid beta in the adult rat brain. Eur J Neurosci 20:896–902.
  • Cramer PE, Cirrito JR, Wesson DW, Lee CY, Karlo JC, Zinn AE, et al. 2012. ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. Science 335:1503–1506.
  • Dean OM, Data-Franco J, Giorlando F, Berk M. 2012. Minocycline: therapeutic potential in psychiatry. CNS Drugs 26:391–401.
  • Dheen ST, Jun Y, Yan Z, Tay SS, Ling EA. 2005. Retinoic acid inhibits expression of TNF-alpha and iNOS in activated rat microglia. Glia 50:21–31.
  • Ding Y, Qiao A, Wang Z, Goodwin JS, Lee ES, Block ML, et al. 2008. Retinoic acid attenuates beta-amyloid deposition and rescues memory deficits in an Alzheimer's disease transgenic mouse model. J Neurosci 28:11622–11634.
  • Dixon KS, Hassoun A. 2010. Pseudotumor cerebri due to the potentiation of all-trans retinoic acid by voriconazole. J Am Pharm Assoc (2003) 50:742–744.
  • Friedman DI. 2005. Medication-induced intracranial hypertension in dermatology. Am J Clin Dermatol 6:29–37.
  • He Y, Appel S, Le WD. 2001. Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum. Brain Res 909:187–193.
  • Hellmann-Regen J, Gertz K, Uhlemann R, Colla M, Endres M, Kronenberg G. 2012. Retinoic acid as target for local pharmacokinetic interaction with modafinil in neural cells. Eur Arch Psychiatry Clin Neurosci 262:697–704.
  • Hellmann-Regen J, Herzog I, Fischer N, Heuser I, Regen F. 2014. Do tetracyclines and erythromycin exert anti-acne effects by inhibition of P450-mediated degradation of retinoic acid? Exp Dermatol 23:290–293.
  • Hellmann-Regen J, Heuser I, Regen F. 2013a. UV-A emission from fluorescent energy-saving light bulbs alters local retinoic acid homeostasis. Photochem Photobiol Sci 12:2177–2185.
  • Hellmann-Regen J, Kronenberg G, Uhlemann R, Freyer D, Endres M, Gertz K. 2013b. Accelerated degradation of retinoic acid by activated microglia. J Neuroimmunol 256:1–6.
  • Hellmann-Regen J, Kronenberg G, Uhlemann R, Freyer D, Endres M, Gertz K. 2013c. Accelerated degradation of retinoic acid by activated microglia. J Neuroimmunol 256:1–6.
  • Hellmann J, Juttner R, Roth C, Bajbouj M, Kirste I, Heuser I, et al. 2011. Repetitive magnetic stimulation of human-derived neuron-like cells activates cAMP-CREB pathway. Eur Arch Psychiatry Clin Neurosci 262:87–91.
  • Hellmann J, Rommelspacher H, Muhlbauer E, Wernicke C. 2010. Raf kinase inhibitor protein enhances neuronal differentiation in human SH-SY5Y cells. Dev Neurosci 32:33–46.
  • Katsuki H, Kurimoto E, Takemori S, Kurauchi Y, Hisatsune A, Isohama Y, et al. 2009. Retinoic acid receptor stimulation protects midbrain dopaminergic neurons from inflammatory degeneration via BDNF-mediated signaling. J Neurochem 110:707–718.
  • Kelly RG, Kanegis LA. 1967. Metabolism and tissue distribution of radioisotopically labelled minocycline. Toxicol Appl Pharmacol 11:171–183.
  • Kim JH, Yu KS, Jeong JH, Lee NS, Lee JH, Jeong YG, et al. 2013. All-trans-retinoic acid rescues neurons after global ischemia by attenuating neuroinflammatory reactions. Neurochem Res 38:2604–2615.
  • Levkovitz Y, Mendlovich S, Riwkes S, Braw Y, Levkovitch-Verbin H, Gal G, et al. 2010. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry 71:138–149.
  • Maden M. 2007. Retinoic acid in the development, regeneration and maintenance of the nervous system. Nat Rev Neurosci 8:755–765.
  • McCaffery P, Zhang J, Crandall JE. 2006. Retinoic acid signaling and function in the adult hippocampus. J Neurobiol 66: 780–791.
  • McCaffery PJ, Adams J, Maden M, Rosa-Molinar E. 2003. Too much of a good thing: retinoic acid as an endogenous regulator of neural differentiation and exogenous teratogen. Eur J Neurosci 18:457–472.
  • McSorley LC, Daly AK. 2000. Identification of human cytochrome P450 isoforms that contribute to all-trans-retinoic acid 4-hydroxylation. Biochem Pharmacol 60:517–526.
  • Melnik B, Bros U, Plewig G. 1987. Characterization of apoprotein metabolism and atherogenic lipoproteins during oral isotretinoin treatment. Dermatologica 175(Suppl 1):158–68.
  • Melnik BC. 2014. The P450 system and mTORC1 signalling in acne. Exp Dermatol 23:318–319.
  • Melnik BC, Schmitz G. 2013. Are therapeutic effects of antiacne agents mediated by activation of FoxO1 and inhibition of mTORC1? Exp Dermatol 22:502–504.
  • Mey J, Morassutti DJ, Brook G, Liu RH, Zhang YP, Koopmans G, et al. 2005. Retinoic acid synthesis by a population of NG2-positive cells in the injured spinal cord. Eur J Neurosci 21:1555–1568.
  • Miyaoka T, Wake R, Furuya M, Liaury K, Ieda M, Kawakami K, et al. 2012. Minocycline as adjunctive therapy for patients with unipolar psychotic depression: an open-label study. Prog Neuropsychopharmacol Biol Psychiatry 37:222–226.
  • Molina-Hernandez M, Tellez-Alcantara NP, Perez-Garcia J, Olivera-Lopez JI, Jaramillo-Jaimes MT. 2008. Antidepressant-like actions of minocycline combined with several glutamate antagonists. Prog Neuropsychopharmacol Biol Psychiatry 32:380–386.
  • Moskowitz Y, Leibowitz E, Ronen M, Aviel E. 1993. Pseudotumor cerebri induced by vitamin A combined with minocycline. Ann Ophthalmol 25:306–308.
  • Niwa T, Murayama N, Yamazaki H. 2009. Oxidation of endobiotics mediated by xenobiotic-metabolizing forms of human cytochrome. Curr Drug Metab 10:700–712.
  • Oliveira GB, Fontes Ede A, Jr, de Carvalho S, da Silva JB, Fernandes LM, Oliveira MC, et al. 2014. Minocycline mitigates motor impairments and cortical neuronal loss induced by focal ischemia in rats chronically exposed to ethanol during adolescence. Brain Res 1561:23–34.
  • Regen F, Heuser I, Herzog I, Hellmann-Regen J. 2013. Striking Growth-inhibitory effects of minocycline on human prostate cancer cell lines. Urology 83:509.
  • Reijntjes S, Gale E, Maden M. 2004. Generating gradients of retinoic acid in the chick embryo: Cyp26C1 expression and a comparative analysis of the Cyp26 enzymes. Dev Dyn 230:509–517.
  • Reus GZ, Abelaira HM, Maciel AL, Dos Santos MA, Carlessi AS, Steckert AV, et al. 2014. Minocycline protects against oxidative damage and alters energy metabolism parameters in the brain of rats subjected to chronic mild stress. Metab Brain Dis 30:545–553.
  • Savitz J, Preskorn S, Teague TK, Drevets D, Yates W, Drevets W. 2012. Minocycline and aspirin in the treatment of bipolar depression: a protocol for a proof-of-concept, randomised, double-blind, placebo-controlled, 2x2 clinical trial. BMJ Open 2:e000643.
  • Shearer KD, Fragoso YD, Clagett-Dame M, McCaffery PJ. 2012a. Astrocytes as a regulated source of retinoic acid for the brain. Glia 60:1964–1976.
  • Shearer KD, Stooney PN, Nanescu SE, Helfer G, Barrett P, Ross AW, et al. 2012b. Photoperiodic expression of two RALDH enzymes and the regulation of cell proliferation by retinoic acid in the rat hypothalamus. J Neurochem 122:789–799.
  • Shi LF. 2007. Tetracycline-family antibiotics and pseudotumor cerebri. J Am Acad Audiol 18:453–454; author reply 454.
  • Thatcher JE, Isoherranen N. 2009. The role of CYP26 enzymes in retinoic acid clearance. Expert Opin Drug Metab Toxicol 5:875–886.
  • Tian Y, Guo S, Wu X, Ma L, Zhao X. 2015. Minocycline alleviates sevoflurane-induced cognitive impairment in aged rats. Cell Mol Neurobiol 35:585–594.
  • Wagner M, Han B, Jessell TM. 1992. Regional differences in retinoid release from embryonic neural tissue detected by an in vitro reporter assay. Development 116:55–66.
  • Yong VW, Wells J, Giuliani F, Casha S, Power C, Metz LM. 2004. The promise of minocycline in neurology. Lancet Neurol 3:744–751.
  • Yrjanheikki J, Tikka T, Keinanen R, Goldsteins G, Chan PH, Koistinaho J. 1999. A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc Natl Acad Sci USA 96:13496–13500.
  • Zhao XJ, Ishizaki T. 1999. A further interaction study of quinine with clinically important drugs by human liver microsomes: determinations of inhibition constant (Ki) and type of inhibition. Eur J Drug Metab Pharmacokinet 24: 272–278.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.